课题基金 / 基金详情

Sparking Advancements in Genomic Medicine

Sparking Advancements in Genomic Medicine
激发基因组医学的进步
批准号:
10629549
负责人:
Larisa Humma Cavallari
金额:
$75.04万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
未结题
起止时间:
2013-06-16 至 2025-06-30

项目摘要

项目成果

Larisa Humma Cavallari的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要 作为IGNITE II网络的一部分,两项前瞻性、随机、实用、基因型指导的临床试验, GUARDD-US和Adit-PGx分别于2019年7月和2021年2月开始实施。这些 试验将有助于确定实施基因测试对高血压、抑郁症和疼痛的影响 治疗。GUARDD-US:慢性肾脏疾病(CKD)与高血压有关。有非洲血统的人 血统(AA)患CKD和肾衰竭的风险最高,高血压的患病率最高,以及 血压(BP)控制率最低。虽然这种差距在一定程度上是由社会决定因素造成的, 祖先有生物学基础和APOL1高风险基因变异,几乎是在AAs中发现的, 肾衰竭风险增加10倍。我们建议进行一项以基因型为导向的试验,以确定早期与非早期的疗效。 延迟得知APOL1基因分型对3个月的收缩压(SBP)的阳性结果。这场审判 旨在招募患有高血压的非裔美国人,有或没有CKD,随机分为即刻和 延迟返回APOL1基因检测。对于APOL1阴性的患者,我们还将进行一项初步研究 目的:测试药物遗传学(PGx)试验对SBP的影响。领养-PGx:疼痛和抑郁是条件 这影响了相当大比例的美国人口。急慢性疼痛的治疗面临挑战 很难找到有效的治疗方法,同时将不良反应或阿片成瘾的风险降至最低。为 抑郁症,几乎没有临床上相关的预测治疗成功的指标,这导致治疗不充分。 对很多病人来说都是治疗。我们提出了一项前瞻性、随机、实用、以基因型为导向的临床试验 在以下三种情况下测试基因引导疗法的效果:急性术后疼痛、慢性疼痛 疼痛和抑郁。在每种情况下,参与者将被随机接受基因引导的药物治疗 而不是通常的药物治疗选择方法。患者报告的代表疼痛的结果的变化 而使用标准PROMIS量表的抑郁症控制定义了主要终点。二次分析 包括安全终点、总体幸福感的变化,以及由 医疗保健利用率。目前的行政补充要求在很大程度上反映了5/9年的审判需要 由于采用-PGx和GUARDD-US试验的意外全网延迟和因以下原因而关闭 新冠肺炎。此外,此管理请求反映了UF临床集团(CG)的100名注册人数 增加急性疼痛试验的参与者,使UF的注册目标达到850名参与者。
英文摘要
Project Summary As part of the IGNITE II network, two prospective randomized pragmatic genotype-guided clinical trials, GUARDD-US and ADOPT-PGx, have been underway since July 2019 and February 2021, respectively. These trials will help to determine the impact of implementing genetic testing on hypertension, depression, and pain therapies. GUARDD-US: Chronic kidney disease (CKD) is associated with hypertension. People with African ancestry (AAs) have the highest risk of CKD and kidney failure, the highest prevalence of hypertension, and the lowest rate of blood pressure (BP) control. While this disparity is in part due to social determinants, ancestry has biological underpinnings and APOL1 high-risk genetic variants, nearly exclusive found in AAs, increase kidney failure risk 10-fold. We propose a genotype-guided trial to determine the effect of early vs. delayed knowledge of a positive APOL1 genotyping result on 3-month systolic blood pressure (SBP). The trial aims to recruit African Americans with hypertension, with or without CKD, randomized to immediate versus delayed return of APOL1 genetic testing. In those who are APOL1 negative, we will also conduct a pilot study to test the impact of pharmacogenetic (PGx) testing on SBP. ADOPT-PGx: Pain and depression are conditions that impact substantial proportions of the US population. The treatment of acute and chronic pain is challenged by the difficulty of finding effective therapies while minimizing the risk of adverse effects or opioid addiction. For depression, there are few clinically relevant predictors of successful treatment, which results in inadequate therapy for many patients. We propose a prospective randomized pragmatic genotype-guided clinical trial that tests the effect of genotype-guided therapy in three scenarios of patients: acute post-surgical pain, chronic pain, and depression. For each scenario, participants will be randomized to genotype-guided drug therapy versus usual approaches to drug therapy selection. Changes in patient reported outcomes representing pain and depression control using standard PROMIS scales define the primary endpoints. Secondary analyses include safety endpoints, changes in overall well-being, and economic impact represented by differences in healthcare utilization. The current administrative supplement request reflects trial needs for Year 5/9 largely due to unanticipated network-wide delays with the ADOPT-PGx and GUARDD-US trials and shutdowns due to COVID-19. In addition, this administrative request reflects the UF Clinical Group’s (CG) enrollment of 100 additional participants for the Acute Pain Trial, bringing UF’s enrollment goal to 850 participants.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IGNITE Cost Extension - Admin Supplement
  • 批准号:
    10820198
  • 项目类别:
  • 资助金额:
    $135.18万
  • 财政年份:
    2023
  • 负责人:
    Larisa Humma Cavallari
  • 依托单位:
Sparking Advancements in Genomic Medicine
  • 批准号:
    10553452
  • 项目类别:
  • 资助金额:
    $62.33万
  • 财政年份:
    2022
  • 负责人:
    Larisa Humma Cavallari
  • 依托单位:
Precision antiplatelet therapy after percutaneous coronary intervention
  • 批准号:
    10192818
  • 项目类别:
  • 资助金额:
    $71.81万
  • 财政年份:
    2020
  • 负责人:
    Larisa Humma Cavallari
  • 依托单位:
Precision antiplatelet therapy after percutaneous coronary intervention
  • 批准号:
    10636869
  • 项目类别:
  • 资助金额:
    $68.27万
  • 财政年份:
    2020
  • 负责人:
    Larisa Humma Cavallari
  • 依托单位:
海外基金